Wolverine stack[BPC-157 + TB-500 blend]
Compound snapshot
Class
Informal community blend
FDA approved
Research use only — an informal community blend, not an approved medicine
Clinical development
Discovery
Last reviewed
September 2026
Research areas
Community blend / Recovery / Tissue repair
Regulatory status
Research use only — an informal community blend, not an approved medicine
Internet attention
High
Registry query
Wolverine stack
A two-peptide blend of BPC-157 and TB-500, usually co-freeze-dried in one vial so both share a single diluent volume. The name comes from user communities, not from a manufacturer or a regulator.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- Discussed as the 'core' repair pairing for tendon, ligament and muscle injury models
- Each component has its own animal-model repair literature
- One vial rather than two is the practical reason blends exist
Mechanistically plausible
- The two components are described through different pathways: BPC-157 is studied for nitric-oxide and VEGFR2-linked blood-vessel growth and tendon-cell migration, while TB-500 (a thymosin beta-4 fragment) binds actin and is studied for cell migration and wound closure. Combining them is a rationale, not a demonstrated synergy.
Common internet claims
- Online discussion frequently presents Wolverine stack as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Wolverine stack, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
The two components are described through different pathways: BPC-157 is studied for nitric-oxide and VEGFR2-linked blood-vessel growth and tendon-cell migration, while TB-500 (a thymosin beta-4 fragment) binds actin and is studied for cell migration and wound closure. Combining them is a rationale, not a demonstrated synergy.
- Discussed as the 'core' repair pairing for tendon, ligament and muscle injury models
- Each component has its own animal-model repair literature
- One vial rather than two is the practical reason blends exist
Strength of the evidence: No study has tested this combination in any species. All supporting data are single-compound animal studies; because both components share a vial, a result can never be attributed to one of them.
Safety and known cautions
Neither BPC-157 nor TB-500 is an approved medicine. An FDA advisory committee voted in July 2026 to recommend both for the 503A compounding list, but that vote is non-binding and neither can be legally compounded until the FDA completes rulemaking; both are WADA-prohibited in sport. Unregulated vials vary in purity and in the mass of each component. Long-term safety, and any effect on existing tumours through blood-vessel growth, is unknown.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- DiscoveryCurrent
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- Approved